Objective: To describe the new Medicare and Medicaid waste, fraud, and abuse provisions of the Affordable Care Act (H.R. 3590) and Health Care and Education Affordability Reconciliation Act of 2010 (H.R. 4872), the preexisting law modified by H.R. 3590 and H.R. 4872, and applicable existing and proposed regulations.
Learning objectives
At the conclusion of this program, the pharmacist will be able to: n Differentiate between the effective dates for the new screening and enrollment requirements for "new providers" and previously enrolled providers. n Identify the standard of liability under the federal False Claims Act, practices that may subject health care providers to civil penalties, and the new penalty amounts under the new law. D uring the previous 10 years, numerous settlements have occurred between the government and large health care providers, including pharmaceutical companies, pharmacies, and hospital chains, over fraud and false claims. In 2000, the Hospital Corporation of America, which was the largest hospital chain at that time, agreed to a settlement of more than $840 million in criminal and civil fees. 1 In 2001, TAP Pharmaceuticals agreed to pay more than $875 million for fraudulent pricing and claims. 2 In 2006, the Tenet Healthcare Corporation entered into a $900-million settlement regarding fraudulent billing and kickbacks, and in that same year, St. Barnabas Health Care System (the largest health care system in New Jersey) paid $265 million to resolve allegations that nine of its hospitals fraudulently increased charges to elderly patients to obtain enhanced Medicare reimbursement for outlier claims. 3 In 2008, CVS Caremark agreed to pay $36.7 million to resolve its liability based on allegations that it improperly switched drugs that it billed to Medicaid programs in 23 states. 4 These settlements were all eclipsed by the 2009 payment by Eli Lilly of $1.4 billion in civil and $515 million in criminal fines for off-label drug promotions, and Pfizer paid $2.3 billion to settle allegations of off-label drug promotion and other violations. 5 These high settlement amounts show the prevalence of fraud and abuse in the system and the government's increasing diligence when it comes to enforcing these laws.
In 2009, Medicare covered 45.5 million beneficiaries at a total cost of $486 billion; Medicaid had 51 million beneficiaries and cost the federal government $217 billion. 6 The Centers for Medicare & Medicaid Services (CMS) estimated that improper payments for Medicare fee-for-service alone totaled $24.1 billion. 7 Some have estimated that waste, fraud, and abuse cost as much as $100 billion a year. 8 The Affordable Care Act (ACA) 9 and the Health Care and Education Reconciliation Act 10 signed into law by President Barack Obama in March 2010 promise to reduce health care expenditures by enacting stricter provisions against waste, fraud, and abuse in the system. The new legislation includes many antifraud and program integrity initiatives, including new transparency requirements, provider screening and enrollment requirements, amendments to federal antifraud tools, waste prevention that is specific to pharmacies, new ways to review postpayment claims, and increased penalties for offenders. 11 With health care costs expected to continue to increase, the government has targeted providers and suppliers that intentionally defraud government programs and ones that unintentionally cause these programs to make improper payments.
The government will spend $290 million during the next 10 years to combat Medicare and Medicaid fraud and abuse.
12 Most of the money will go to government agencies so that they can better monitor and combat waste, fraud, and abuse. On 13 HEAT will use advanced data analysis techniques to identify potentially criminal activity among health care providers and to detect fraud schemes. It also will focus on new prevention techniques.
14 In addition, CMS will contract with private companies to audit the federal and state health care programs; this will include Recovery Audit Contractors (RACs) that will audit providers for overpayments and Zone Program Integrity Auditors (ZPICs) that will monitor for fraud and abuse. 15 
New screening requirements
New screening and enrollment requirements will affect all providers, including pharmacists who provide services to Medicare, Medicaid, and Children's Health Insurance Programs. 16 Before ACA was passed, no provider screenings occurred, although providers were required to disclose criminal records. The new screening requirements will include a licensure check, a criminal background check, fingerprinting, unscheduled and unannounced visits, database checks, and other appropriate screening. 17 This provision also requires that providers seeking to enroll or reenroll must disclose any current or previous affiliations with any other provider or supplier that has uncollected debt or has been suspended or excluded from any federal health care program. 18 New providers (i.e., providers who were not enrolled in any of the programs before March 23, 2010) will be subject to the new enrollment and screening requirements beginning March 2011. Providers who were enrolled before March 2010 will not be subject to the screenings until March 2012. Providers who are seeking to revalidate their enrollment
Assess your knowledge
Take a moment to assess your current knowledge by reviewing the case study and answering the following questions. The answers to case study questions appear later in the article.
Physician A owns a practice in a rural town with a population of 4,000. The town only has a few physicians and one community chain pharmacy. Seeing a business opportunity, physician A solicits pharmacist B to join physician A in a partnership to develop a new community pharmacy in town. Physician A contributes the capital necessary to rent the storefront and acquire the initial inventory, and pharmacist B will provide management and the operation of the store's pharmacy. Pharmacist B will be paid a small salary and receive a 30% equity share of the partnership, with the physician receiving the remaining 70%. In addition to the profits allocated by the structure of the partnership, physician A also will be allocated an additional 10% share of the profits from each patient that physician A refers to the pharmacy, but no such allocation will be made to physician A if the patient is sourced from another physician.
With the new pharmacy up and running, physician A starts referring patients, including a number of Medicaid patients, to the new pharmacy. As an added incentive for patients to go to the new pharmacy, physician A arranges with pharmacist B for the new pharmacy to offer a 5% rebate on the cost of drugs or coinsurance to any patients (regardless of Medicare enrollment) bringing a script from physician A. 1. Are there potential problems with the ownership and profitsharing structure of the new pharmacy? 2. Is the 5% rebate program offered by the new pharmacy proper?
must be screened if they revalidate after September 19, 2010 . Last, no provider will be able to receive payment from any federal program after March 23, 2013, if he or she has not been screened. 19 
False claims
The federal False Claims Act (FCA) 20 originated during the Civil War to prevent people from selling faulty animals, guns, ammunition, and other provisions to the U.S. government. Fines could result if false claims were made about an item in order to obtain money from the government. 21 Today, FCA is used by the government to recover improper or false payments made by government health care programs to providers or suppliers. A person is liable under FCA when that person "knowingly presents, or causes to be presented, a false or fraudulent claim for payment or approval."
22
In pharmacy, FCA violations usually occur because of inappropriate billing practices such as up-coding, billing for nonexistent prescriptions, billing for brand-name drugs when generics are dispensed, billing prescriptions that were never picked up, and other forms of fraudulent behavior directed at Medicare or Medicaid. 23 These are considered false claims because the pharmacist is intentionally making a claim for reimbursement for services that were not rendered or were rendered in a manner different from what was claimed.
FCA itself was not changed by the health care reform (HCR) legislation, but civil monetary penalties were increased for false claims made to federal health care programs. 24 The fine for making a false claim to a health care program increased from $10,000 to $50,000 plus three times the amount of the claim for each false statement or record. In addition, a fine of $15,000 per day results if the provider or supplier does not allow access to HHS for audits or other investigations. 25 An overpayment made by a federal health care program also will be considered an "obligation" under FCA if it is not paid within 60 days from when the overpayment was identified. 26 Whether the overpayment will be considered a false claim under FCA is unclear, but identifying an overpayment as an obligation under FCA indicates that liability could exist under the act. These provisions are meant to compel providers and suppliers to comply with all rules and regulations attached to government health care program reimbursement and to be prompt when an overpayment has been identified.
Antikickback
The Medicare antikickback statute (AKS) 27 underwent two major changes after ACA was passed. 28 First passed in 1972, AKS prohibits anyone from "knowingly and willfully soliciting or receiving any remuneration directly or indirectly under a federal healthcare program" or "knowingly and willfully offering or paying any remuneration directly or indirectly under a federal healthcare program." 29 AKS essentially prohibits the exchange of remuneration for patient referrals or for goods and services that may be covered in part or wholly by a government-funded plan. Over the years, the Social Security Act continued to be amended, transforming AKS from a misdemeanor to a felony. Currently, violating the provision can result in criminal prosecution, including a maximum $25,000 fine and 5 years in prison. 30 Civil penalties for violating AKS include a $50,000 fine and a "three strikes" provision mandating permanent exclusion from federal health care programs for providers guilty of three health care-related offenses. 31 Traditionally, prosecutors have enforced AKS by focusing on transactions between a person or entity making a referral and the recipient of the referral. 32 Prosecutors then would gather evidence that would indicate a higher amount of referrals flowing from one entity to another and evidence of abovemarket payments between the two. 33 In 1985, the Third Circuit ruled that even if payments were made to compensate the provider for professional services, if one purpose of the payments is to induce referrals-even if it is not the primary purposethen a violation of AKS has occurred. 34 Following that ruling, AKS became a broad tool that the government could use to prosecute health care providers for a range of different practices. In one case, a manager of a nursing home in Michigan contracted with pharmacies that supplied his patients (who were primarily Medicaid patients) with supplies and services in exchange for alcoholic beverages. 35 In a high-profile case, TAP Pharmaceuticals settled with the government and paid more than $875 million in criminal and civil fines for providing free samples of drugs to physicians and then encouraging them to bill Medicare for the medications. 36 The cases have ranged from clearly criminal behavior to providers waiving copayments and deductibles for beneficiaries.
AKS has a much broader reach than other fraud and abuse statutes. It no longer implicates only payments for referrals made under Medicaid or Medicare. Any payment for ordering, providing, leasing, furnishing, recommending, or arranging for the provision of any service, item, or good payable by a federal program is suspect under AKS. Almost any type of economic benefit that can flow to anyone capable of increasing business with government program beneficiaries can be scrutinized, and all parties to an arrangement are liable to both civil and criminal prosecution. 37 Because of this, many health care providers have expressed concern that they could be prosecuted for engaging in regular business practices. This led the government to create safe-harbor regulations specifying various types of practices that are immune to prosecution under AKS. 38 A total of 25 safe-harbor regulations have been promulgated to protect commonplace business practices from AKS. 
Practice check
Does your organization teach its personnel to spot fraudulent behavior directed at Medicare or Medicaid?
practices, but they all come with detailed conditions. For instance, the personal services safe harbor requires seven conditions to be met before a payment made by a principal to an agent will be considered a legal remuneration. 40 These standards include the following: (1) that the agreement is in writing and is signed by both parties, (2) that the agreement covers all services that the agent will provide to the principals, (3) that the agreement specifies whether the services will provided on a part-time or full-time basis and the exact schedule of the activities, (4) that the agreement is for more than a year, (5) that the aggregate compensation paid is set in advance and at fair market value and does not take into account the volume or value of any referrals generated, (6) that the services performed do not violate federal or state law, and (7) that the aggregate services contracted for do not exceed those that are reasonably necessary to accomplish the business purpose of the services. 41 The personal services safe harbor is one of the least complicated safe-harbor provisions, but in other industries, a principalagent relationship would not be required for any of these conditions (Table 1) .
HCR introduced two important changes to AKS that dramatically increased the potential liability of providers. For several years, AKS has been used in conjunction with FCA to increase liability for violating the statute. 42 When a violation of AKS is prosecuted along with FCA, each violation can cost the defendant up to $50,000 plus three times the amount of the damages sustained by the government. 43 ACA changed the law so that any violation of AKS constitutes a false claim under FCA. 44 As a result of that change, prosecutors no longer have to prove or establish a connection between a false claim and a violation of AKS. 45 In addition to making an AKS violation the equivalent of a false claim, ACA also changed the intent requirement. 46 The Ninth Circuit had established that to violate AKS, the defendant needed to know the statute's proscriptions and intend to violate them. 47 This requirement is difficult to prove; therefore, the government has not used AKS as a basis for prosecution as frequently as other fraud and abuse statues. Under ACA, the intent requirement has been reduced to "a person need not have actual knowledge of this section or specific intent to commit a violation of this section." 48 This change could result in substantial criminal and civil exposure for providers even if they did not intend to violate the statute. Whether this occurs will become clearer as defendants are tried under the new law in court. 49 Both of the changes made by the HCR legislation greatly increase liability for providers who violate AKS. All claims made to Medicare and Medicaid arising from a violation of AKS will constitute false claims and carry the additional costs. 50 With the increased liability, pharmacists and other providers will have to be more diligent when engaging in a transaction or other arrangement with other providers or suppliers.
Remuneration
The new exceptions made to the definition of "remuneration" could be advantageous for pharmacies. 51 Federal law prohibits providers from offering patients covered by any government health care program certain inducements (e.g., discounts, other remunerations) if the provider "knows or should know" that the inducement "is likely to influence such individual to order or receive from a particular provider, practitioner, or supplier
Practice check
What checks does your organization have in place to ensure that a new or ongoing business practice does not run afoul of AKS? To whom in your organization can you direct a question regarding AKS? This table is only designed to be a summary of potentially available exemptions to AKS. Each safe harbor has its own specific criteria that must be met for the business practice to be eligible, and the regulations should be consulted before relying on the safe harbor.
any item or service for which payment may be made, in whole or in part, under a government program"; in short, remunerations are treated like kickbacks. 52 The blanket prohibition against remuneration prevented pharmacies from giving out coupons or other types of rewards to patients covered by any government program. 53 In addition, any violation of this law was treated like a false claim, and the provider could be liable for $10,000 for each claim plus three times the amount of each claim.
54
Remuneration has been defined as anything having value but offered for free or for a price different than its fair market value. 55 The only exception allowed, until 2002, was the waiver of copays and deductibles under certain conditions: (1) 56 In 2002, OIG created a new exception to the law that allowed providers to "offer inexpensive gifts or services, that have the retail value of no more than $10 individually and no more than $50 in the aggregate annually per patient."
57 This law was difficult for pharmacies and other providers to work with because tracking the $50 annual limit was difficult. 58 In 2007, OIG allowed a rewards program offered by warehouse clubs that operated community pharmacies. This program offered customers rewards of less than 5% of what they had spent at the warehouses, including spending on prescription drugs. OIG decided not to impose sanctions because the program presented a "minimal risk" of abuse and the rewards were not "tied" to drug purchases.
59
The HCR legislation added four new exceptions to the remuneration statute. The first exception allows any remuneration that promotes access to care and poses a low risk of harm to patients and the government health programs. 60 The second exception allows providers to offer or transfer items or services for free or less than market value if the items or services consist of coupons, rebates, or other rewards. These coupons or rebates must be transferred on equal terms and to the general public, and they cannot be tied to the provision of other items or services reimbursed by a government health program. 61 The third exception allows providers to offer items or services for free or for less than market value if they are not offered as part of any advertisement, if they are not tied to the provision of other services reimbursed by a government health program, if a reasonable connection exists between the items and services and the medical care of the patient, and if those items or services are provided only after a good faith determination that the patient is in financial need occurs. 62 The final exception allows Medicare Part C and D sponsors to offer to waive the copayment for the first refill of a covered Part D drug if it is a generic. 63 OIG has not interpreted these new exceptions; therefore, pharmacies should wait before designing new rewards programs. Section F, 64 which allows "any other remuneration which promotes access to care and poses a low risk of harm to patients and federal health care programs," is very broad; thus, guidance is needed before providers use that statute to offer rewards. In addition, how "retailer" will be defined in section G 65 is unclear; there is no guarantee that it will include pharmacies. 66 No date has been set for when OIG or HHS will have to begin writing regulations for these new provisions; therefore, providers should consult their attorneys before offering coupons or rebates to customers.
Stark Law
The Stark Law 67 is very similar to AKS in that it prohibits providers from benefiting from making patient referrals. Stark prohibits a physician from making a referral for designated health services to an entity that the physician or a physician's immediate family member has a financial relationship with; these are known as self-referrals. 68 A financial relationship can mean two things. The first meaning is an ownership or investment interest through equity, debt, or any financial interest other than publicly traded stocks and bonds. Exceptions also exist for rural providers that meet certain conditions. 69 In the second meaning, compensation arrangements that involve a remuneration between a physician and a designated health services entity are prohibited, and this rule has a huge amount of exceptions. 70 Remuneration, as defined in the Stark Law, means any payment or other benefit made directly, indirectly, in cash, or in kind. The exceptions relate to amounts forgiven for certain tests or billing errors, certain specimen collections and related items and supplies, and certain payments by an insurer or self-insured plans and their subcontractors to settle claims. 71 The Stark Law got its name from Representative Fortney "Pete" Stark (D-CA), who pushed for the passage of the Omnibus Budget Reconciliation Act of 1989. 72 Known as Stark I, the law prohibited physicians from referring patients to clinical laboratories with which the physician had a financial relationship. 73 Stark II, passed in 1993, added 11 more designated health services and introduced the first exceptions to the law. 74 Currently, there are 12 designated health services: (1) clinical laboratory services; (2) physical therapy services; (3) occupational therapy services; (4) radiology services, including magnetic resonance imaging, computerized axial tomography scans, and ultrasound services; (5) radiation therapy services and supplies; (6) durable medical equipment and supplies; (7) parenteral and enteral nutrients, equipment, and supplies; (8) prosthetics, orthotics, and prosthetic devices and supplies; (9) home health services; (10) outpatient prescription drugs; (11) inpatient and outpatient hospital services; and (12) outpatient speech/language pathology services. 75 The Stark III rules were
Practice check
Can you identify some referral arrangements in your own practice that, if implemented, would violate the Stark Law? Does your organization have referral procedures in place to prevent Stark violations?
HCR WASTE, FRAUD, AND ABUSE REVIEWS put into the Federal Register in 2007, and these were considered the final rules until ACA introduced some new provisions on self-disclosures.
76
Unlike AKS, a person does not actually have to intend to violate the Stark Law. Strict liability exists: If a physician knows or should have known that he or she is making a self-referral, that person can be subject to civil monetary penalties. 77 For each service performed under a self-referral, the provider could be fined up to $15,000; the government also can fine a provider (e.g., pharmacy) $100,000 if the provider entered into an arrangement or scheme to make illicit referrals. 78 There are indications that under ACA's new overpayment provisions, each claim billed to Medicare or Medicaid that involved a Stark violation could be considered an overpayment if it is not paid back within 60 days from when it should have been discovered. If that is the case, each overpayment could cost the provider $50,000 plus three times the amount of the claim. 79 In 1998, OIG released the first self-disclosure protocol (SDP) so that providers who violated the Stark Law could disclose the illegal relationship and then negotiate the return of at least some of the claims to the government. 80 In April 2006, OIG released another Open Letter to Providers that further encouraged providers to come forward by offering general commitment to resolving the matters on the "lower end of the damages spectrum," which essentially meant that providers would be fined the minimum instead of the maximum amount. 81 In March 2009, OIG issued another Open Letter announcing that it would no longer accept providers into SDP just for Stark violations; the Stark violation would have to accompany an antikickback violation. 82 OIG also announced that the minimum settlement would be $50,000 and up to three times the value of the claim.
83
ACA's change to the Stark Law concerns SDP only and turns it into the self-referral disclosure protocol (SRDP). For the first time, the authority officially has been given to HHS to reduce the amount owed by the provider.
84 HHS was to establish the SRDP officially in September 2010, and the agency will provide information for a specific official or office to which disclosures will be made and instructions on the implication of SRDP on corporate integrity agreements and corporate compliance agreements. 85 Four factors have been introduced that HHS will use to determine the amount due for a violation: (1) the nature and extent of the improper or illegal practice, (2) the timeliness of the disclosure, (3) cooperation in providing additional information related to the disclosure, and (4) other factors that the secretary considers appropriate. 86 Most of the issues surrounding SRDP have not been addressed, but when the rules begin to emerge in the coming months, more light should be shed on this process.
Recovery audit contractors
Not all improper payments made by government health care programs result from illegal referrals or intentional false claims. In fact, the bulk of improper claims are based on medically unnecessary treatment and incorrectly coded claims that mainly are the result of billing mistakes rather than fraud. 87 Improper claims can occur for a number of reasons: (1) payments made for services that do not meet Medicare's medical necessity criteria, (2) payments made for services that were incorrectly coded, (3) proper documentation not submitted by providers upon request, (4) claims based on outdated fee schedules, and (5) duplicate claims submitted. 88 In 2008, Medicare processed more than 1.2 billion claims that were submitted by more than 1 million providers. 89 HHS estimated that between April 2008 and March 2009, $24.1 billion dollars (or 7.8% of claims) were spent on improper claims for Medicare Parts A and B. 90 As a partial solution to this problem, CMS devised a plan to use private companies (i.e., RACs) to review postpayment claims data and identify improper payments.
In December 2003, Congress passed the Medicare Prescription Drug, Improvement, and Modernization Act (MMA), 91 which authorized CMS to complete a demonstration project to determine whether RACs could be used effectively to track improper payments made by Medicare. 92 In March 2005, CMS contracted with three private RACs for the demonstration. 93 California, New York, and Florida were chosen for the initial part of the demonstration because they are the three largest states in terms of Medicare use. 94 Each RAC was assigned a single state and sent approximately 400 million claims to audit. 95 In December 2006, the Tax Relief and Health Care Act   96 was passed, making RACs permanent and authorizing the expansion of the program to all states by January 2010. 97 In 2007, the demonstration program expanded to include Massachusetts, Arizona, and South Carolina. 98 Today, four RACs are operating in all 50 states, with each RAC contractor having its own region. 99 CMS published the results of the first RAC demonstration on March 27, 2008. In New York, Florida, and California, the RACs managed to recover $1.03 billion in improper payments; 96% of payments were overpayments that were recovered from providers. 100 Of those claims, 14% were appealed by providers that were audited, and only 4.6% of the claims were overturned on appeal. 101 During that same period, regular Medicare claims processors managed to recover only $13 million in overpayments.
102 RACs work off of contingency fees based on what they recover, with these fees ranging from 9% to 12.5%; therefore, the government does not spend money to recoup overpayments. 103 RACs use two different methods to conduct claims reviews. The first type is an automated review; RACs use proprietary software to analyze claims for overpayments, incorrect codes, and duplicate claims. 104 Automated reviews for making coverage and coding determinations are limited to situations in which a Medicare policy or coding guideline is available and confirmation exists that the service is not covered or that a coding error is present. 105 The second type is a complex review; these reviews are done by licensed physicians and other providers to determine whether the treatment was medically necessary or if that particular service was covered by Medicare. 106 Complex reviews are used in situations in which a service likely was not covered and no Medicare guidelines are available. 107 RACs are a powerful tool to combat overpayments made by government health programs, but because they are not meant to target entities that are engaged in fraud and abuse of the system, certain limitations are imposed on them.
108 RACs can review only claims that have already been paid; they do not review or even have access to prepayment claims data.
109
RACs may use only "targeted reviews." RACs use data analysis techniques to compare historical data before they can target a particular provider, and they cannot target a claim solely because of its high dollar value. 110 Auditors only have a 3-year "look-back" period; therefore, they cannot examine claims that were filed more than 3 years before the review. 111 They also are limited to 10 medical records every 45 days from solo practitioners. RACs may request only 10% of the average monthly Medicare claims, with a maximum of 200 every 45 days, from hospitals. 112 The purpose of these limitations is to ensure that RAC audits do not have too much of a negative impact on patient care.
ACA calls for states to establish programs to contract with RACs by the end of 2010 to begin reviewing improper Medicaid claims. 113 In addition, Medicare will expand its RAC program to cover Part D prescription plans and Medicare Advantage plans starting in 2011. 114 Special rules relating to Parts C and D will be established requiring that RACs (1) ensure that each Medicare Advantage plan under Part C has an established antifraud plan, (2) ensure that each prescription drug plan under Part D has an antifraud plan, (3) examine claims for reinsurance payments to determine whether prescription drug plans submitting such claims incurred costs in excess of the allowable reinsurance costs permitted, and (4) review estimates submitted by prescription drug plans with respect to the enrollment of high-cost beneficiaries and compare these estimates with the number of beneficiaries enrolled by the plans. 115 Because RACs are used more heavily throughout the entire health care system, pharmacists should be aware of the potential that these entities have for disrupting a practice. With the expansion to Medicaid and Medicare Part D, RACs can turn their attention to pharmacies and audit the Medicare and Medicaid claims submitted by the pharmacy. With the 3-year look-back period, pharmacies that have billed government health care programs improperly, even by accident, will be liable and will have to return all overpayments. Even if each overpayment is small, 3 years of claims can add up to a large amount of money.
Zone Program Integrity Contractors
Zone Program Integrity Contractors (ZPICs) were established in 2009 by CMS to audit the integrity of all Medicare-related claims. 116 CMS consolidated the work of Program Safeguard Contractors and Medicare Drug Integrity Contractors into seven ZPIC zones. 117 Unlike RACs, which target billing mistakes, ZPICs will be in charge of auditing providers for fraud and abuse. ZPICs will be paid by CMS; their fee will not be contingent on what they find. 118 ZPICs will use data analysis to detect abnormalities between providers and national trends. They will monitor for patient abuse and harm, multistate fraud, high dollar overpayments, and large fraud patterns. 119 ZPIC audits also may be triggered by referrals from other contractors or beneficiary complaints. 120 After an investigation has started, ZPICs will be authorized to conduct audits, interview beneficiaries and providers, start administrative sanctions (e.g., payment suspensions, Medicare exclusion), and refer providers to law enforcement agencies or recover overpayments. 121 ZPICs will be able to monitor pre-and postpayment claims that have been filed within 3 years of the audit. 122 Every pharmacy, and especially should take steps to prepare for a ZPIC audit, especially large pharmacies. Providers may take the following steps in preparing for an audit: (1) ensure that the fraud and abuse compliance program is active and functioning correctly; (2) designate a point person to handle ZPIC audit requests; (3) develop a multidisciplinary committee that has representation across all departments, so that the entire organization can assist in developing and implementing procedures in case of an audit; and (4) create an intake and tracking system to monitor audit deadlines. 123 If a proper fraud and abuse compliance program is in place and billing is being done correctly, then an audit by either a RAC or ZPIC will most likely not occur. However, the possibility always exists that an audit can occur; therefore, mechanisms should be in place so that everything runs smoothly.
Medication therapy management and nursing home medication dispensing
One way in which ACA plans to combat waste and help Medicare beneficiaries with drug use is through medication therapy management (MTM). MMA recognized the value of MTM by requiring Part D sponsors to design and implement MTM plans for certain Medicare beneficiaries. 124 CMS made changes to the requirements for the MTM plans in 2010, and these changes have been codified in ACA along with a grant program to further encourage pharmacists to use MTM.
125
Federal law defines MTM as "a program of drug therapy management that may be furnished by a pharmacist and that is designed to assure that covered part D drugs under the prescription drug plan are appropriately used to optimize therapeutic outcomes through improved medication use, and to reduce the risk of adverse events, including adverse drug interactions." 126 The plans should include basic provisions that enhance patient understanding of medications to promote appropriate use, increase patient adherence to prescription medication regimens, and help pharmacists detect adverse drug events and patterns of overuse and addiction. 127 Federal regulations require that MTM plans include (1) screening for potential problems resulting from therapeutic duplication, (2) age-/gender-related contradictions, (3) over-and underuse, (4) drug-drug interactions, (5) incorrect drug dosage or duration, (6) drug-allergy contraindications, and (7) clinical abuse/
Practice check
Is your organization ready to respond a ZPIC audit? Can your organization take any additional steps to prepare for a ZPIC audit? misuse of prescription drugs.
128 MTM plans must be developed by licensed pharmacists and physicians, and they must allow patients to opt out.
129
Medicare patients must meet three requirements to qualify for a Medicare MTM program. The patient must have at least two chronic diseases to be targeted, but plans cannot require that a patient have more than three diseases to qualify.
130 Sponsors must target at least four of the following chronic diseases:
hypertension, heart failure, diabetes, dyslipidemia, respiratory disease, bone disease (e.g., arthritis), and mental health disease. 131 Patients must be taking at least two drugs to qualify but must be targeted if they are taking eight or more drugs.
132
The final requirement is the likelihood that the patient will incur an annual cost of at least $3,000 for all Part D drugs. 133 In 2012 and the following years, the amount will be $3,000 plus the annual percentage increase in average per capita aggregate expenditures for Part D drugs for eligible individuals.
134
ACA calls for HHS to begin a program that will offer grants to entities that provide MTM programs that go above and beyond the current requirements. 135 Plans that receive these grants will have to include an array of new requirements and procedures that-it is hoped-will increase the effectiveness of MTM for patients. 136 The Part D plans that receive grants also will have different criteria for who can be enrolled. The patient must take at least four prescribed drugs, take any highrisk medication, have two or more chronic diseases, and have recently undergone a transition of care. 137 This new program was supposed to start on May 1, 2010; however, no news regarding the grants has surfaced, and the funding remains unclear.
ACA also introduced new requirements that will go into effect on March 23, 2012. First, pharmacists or other qualified MTM providers will be required to perform an annual comprehensive medication review furnished person to person or using telehealth technologies; this will include a review of the patient's medications and may result in a recommended medication action plan or other actions in consultation with the patient and input from the prescriber, as well as a written summary of the results. Second, pharmacists or other qualified MTM providers will be required to perform follow-up interventions as warranted. Third, the plan sponsor will assess, at least on a quarterly basis, the medication use of patients who are at risk but are not enrolled in the MTM plan. Fourth, the plan sponsor will have a process to automatically enroll targeted beneficiaries and permit beneficiaries to opt out of enrollment.
138
These new provisions are intended to increase the number of Medicare patients in MTM plans and enhance the quality of MTM plans to increase patient safety. Another hope is that the new MTM requirements will reduce spending by helping to eliminate medication overuse and prevent drug interactions that cause health problems in patients.
To further reduce waste and potential fraud, ACA will require Plan D sponsors to develop uniform dispensing techniques for pharmacies within nursing homes. 139 On January 1, 2012, nursing homes will no longer be allowed to dispense 30-day fills of prescription drugs covered by Medicare. 140 CMS will have to develop new regulations for this particular provision, but the statute states that the monthly dose will be reduced to a weekly, daily, or automated dose.
141

Conclusion
The government is more focused than ever when it comes to weeding out waste, fraud, and abuse in Medicare and Medicaid. Congress is hoping that part of the funding for HCR can come from stopping fraudulent activity that costs billions of dollars, as well as recouping overpayments that cost the government tens of billions of dollars each year. These hopes are pinned on the enhanced penalties, private audits, and increased funding for enforcement. The laws will put a greater burden on providers to monitor their billing practices and business relationships and will require providers to be more responsible for fixing errors and disclosing their relationships.
Regulations that will apply to these laws have not been written, and some of them will not be created for at least a few years. Because these important details are not yet available, providers will have to be even more conservative when it comes to their practices. Violating these laws can cost huge amounts of money in penalties and potentially shut down even the largest providers. Honesty and integrity, combined with awareness of the laws, will go a long way in protecting providers from these great liabilities. 
Under the reforms enacted by
Zone Program Integrity Contractors (ZPICs) differ
from RACs in which of the following ways? a. ZPICs collect a contingency fee based on the amount of improper billing they are able to recover from providers. b. ZPIC investigations are triggered by regional data analysis to spot trends that suggest fraudulent activity or can be tipped by provider or beneficiary complaints. c. ZPICs can only audit records during an investigation. d. ZPICs can only seek to recover overpayments if the investigation reveals improper billing practices.
